Clinical Practice Guidelines for hypertension 2003. Do they clarify or confuse?;Guías sobre el tratamiento de la hipertensión arterial 2003: ¿ aclaran o confunden?

Revista Espanola de Cardiologia

Volumn 56, Issue 10, 2003, Pages 940-943

  Bertomeu Martínez, Vicente ^a  

^a HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

Author keywords

Cardiovascular risk; Hypertension; Hypertension classification; Treatment update

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; DISEASE CLASSIFICATION; DRUG CHOICE; EDITORIAL; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; HYPERTENSION; LIFESTYLE; MEDICAL DECISION MAKING; MEDICAL SOCIETY; ORGANIZATION; PRACTICE GUIDELINE; PUBLICATION; SPAIN; TREATMENT INDICATION;

EID: 0242691100     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13052379     Document Type: Editorial

References (11)

1. González-Juanatey JR, Mazón P, Soria F, Barrios V, Rodríguez-Padial L, Bertomeu V. Actualización (2003) de las guías de práctica clínica de la Sociedad Española de Cardiología en hipertensión arterial. Rev Esp Cardiol 2003;56:487-97.
2. The Seventh Report of Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-72.
3. 3 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
4. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, el al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non diabetic individuals. JAMA 2001;286:421-6.
5. The Sixth Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46.
6. 9 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines Subcommittee. J Hypertens 1999;17:151-83.
7. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frecuency of progression to hypertension in non-hypertensive participants in The Framingham Heart Study. Lancet 2001;358:1682-6.
8. Marrugat J, Solanas P, D'Agostino R, Sullivan L, Ordovás J, Cordón F, et al. Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada. Rev Esp Cardiol 2003;56:253-61.
9. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003.
10. The World Health Report 2002. Reducing risks, promoting healthy life. Geneva: World Health Organization, 2002; p. 58.
11. González-Juanatey JR, Alegría Ezquerra E, Lozano Vidal J, Llisterri Caro J, García Acuña J, González Maqueda I. Impacto de la hipertensión en las cardiopatías en España. Estudio Cardiotens 1999. Rev Esp Cardiol 2001;54:139-49.